CYP2C19 loss‐of‐function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel

Our aim was to investigate in a real‐life prospective patient cohort how CYP2C19 loss‐of‐function (LOF) variants and CYP2C19 inhibitor omeprazole or esomeprazole influence the incidence of cardiovascular events in patients using clopidogrel. Data based simultaneously on these factors are conflicting...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramste, Markus, Ritvos, Markus, Häyrynen, Sergei, Kiiski, Johanna I., Niemi, Mikko, Sinisalo, Juha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582682/
https://www.ncbi.nlm.nih.gov/pubmed/37551775
http://dx.doi.org/10.1111/cts.13608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582682/
https://www.ncbi.nlm.nih.gov/pubmed/37551775
http://dx.doi.org/10.1111/cts.13608

Ejemplares similares